Health Care Sector Update for 02/13/2017: OMED
Top Health-care stocks:
Health-care shares were mainly unchanged in pre-market trade on Monday.
In health-care stocks news, OncoMed Pharmaceuticals ( OMED ) has enrolled and dosed the first patient in a phase 1b clinical trial of its anti-DLL4/VEGF bispecific antibody in combination with paclitaxel in patients with platinum-resistant ovarian cancer.
Shares in the company were unchanged at $8.27 pre-bell. The stock has traded between $7.41 and $15.49 over the past 52 weeks.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.